Comparative  ||| S:0 E:12 ||| JJ
characteristics  ||| S:12 E:28 ||| NNS
of  ||| S:28 E:31 ||| IN
using  ||| S:31 E:37 ||| VBG
isoflurane ||| S:37 E:47 ||| NN
,  ||| S:47 E:49 ||| ,
sevoflurane  ||| S:49 E:61 ||| NN
and  ||| S:61 E:65 ||| CC
target  ||| S:65 E:72 ||| NN
concentration  ||| S:72 E:86 ||| NN
of  ||| S:86 E:89 ||| IN
propofol  ||| S:89 E:98 ||| NN
during  ||| S:98 E:105 ||| IN
reconstructive  ||| S:105 E:120 ||| JJ
operations  ||| S:120 E:131 ||| NNS
on  ||| S:131 E:134 ||| IN
the  ||| S:134 E:138 ||| DT
carotid  ||| S:138 E:146 ||| JJ
arteries  ||| S:146 E:155 ||| NNS
To  ||| S:155 E:158 ||| TO
compare  ||| S:158 E:166 ||| VB
effects  ||| S:166 E:174 ||| NNS
of  ||| S:174 E:177 ||| IN
isoflurane ||| S:177 E:187 ||| NN
,  ||| S:187 E:189 ||| ,
sevoflurane  ||| S:189 E:201 ||| NN
and  ||| S:201 E:205 ||| CC
target  ||| S:205 E:212 ||| NN
concentration  ||| S:212 E:226 ||| NN
of  ||| S:226 E:229 ||| IN
propofol  ||| S:229 E:238 ||| NN
on  ||| S:238 E:241 ||| IN
the  ||| S:241 E:245 ||| DT
systemic  ||| S:245 E:254 ||| JJ
hemodynamics ||| S:254 E:266 ||| NN
,  ||| S:266 E:268 ||| ,
cerebral  ||| S:268 E:277 ||| JJ
blood  ||| S:277 E:283 ||| NN
flow  ||| S:283 E:288 ||| NN
and  ||| S:288 E:292 ||| CC
cerebral  ||| S:292 E:301 ||| JJ
oximetry  ||| S:301 E:310 ||| NN
of  ||| S:310 E:313 ||| IN
the  ||| S:313 E:317 ||| DT
brain  ||| S:317 E:323 ||| NN
during  ||| S:323 E:330 ||| IN
the  ||| S:330 E:334 ||| DT
carotid  ||| S:334 E:342 ||| JJ
endarterectomy ||| S:342 E:356 ||| NN
.  ||| S:356 E:358 ||| .
We  ||| S:358 E:361 ||| PRP
studied  ||| S:361 E:369 ||| VBD
95  ||| S:369 E:372 ||| CD
patients ||| S:372 E:380 ||| NNS
.  ||| S:380 E:382 ||| .
The  ||| S:382 E:386 ||| DT
patients  ||| S:386 E:395 ||| NNS
were  ||| S:395 E:400 ||| VBD
divided  ||| S:400 E:408 ||| VBN
into  ||| S:408 E:413 ||| IN
3  ||| S:413 E:415 ||| CD
groups ||| S:415 E:421 ||| NNS
.  ||| S:421 E:423 ||| .
Group  ||| S:423 E:429 ||| NN
I  ||| S:429 E:431 ||| PRP
included  ||| S:431 E:440 ||| VBD
26  ||| S:440 E:443 ||| CD
patients  ||| S:443 E:452 ||| NNS
who  ||| S:452 E:456 ||| WP
received  ||| S:456 E:465 ||| VBD
isoflurane  ||| S:465 E:476 ||| NNS
( ||| S:476 E:477 ||| -LRB-
under  ||| S:477 E:483 ||| IN
I  ||| S:483 E:485 ||| NNP
MAC ||| S:485 E:488 ||| NNP
) ||| S:488 E:489 ||| -RRB-
,  ||| S:489 E:491 ||| ,
Group  ||| S:491 E:497 ||| NNP
II--40  ||| S:497 E:504 ||| NNP
patients  ||| S:504 E:513 ||| NNS
who  ||| S:513 E:517 ||| WP
received  ||| S:517 E:526 ||| VBD
sevoflurane  ||| S:526 E:538 ||| NNS
( ||| S:538 E:539 ||| -LRB-
under  ||| S:539 E:545 ||| IN
I  ||| S:545 E:547 ||| NNP
MAC ||| S:547 E:550 ||| NNP
) ||| S:550 E:551 ||| -RRB-
,  ||| S:551 E:553 ||| ,
Group  ||| S:553 E:559 ||| NNP
III--29  ||| S:559 E:567 ||| NNP
patients  ||| S:567 E:576 ||| NNS
who  ||| S:576 E:580 ||| WP
received  ||| S:580 E:589 ||| VBD
target  ||| S:589 E:596 ||| NN
concentration  ||| S:596 E:610 ||| NN
of  ||| S:610 E:613 ||| IN
propofol  ||| S:613 E:622 ||| NNS
( ||| S:622 E:623 ||| -LRB-
under  ||| S:623 E:629 ||| IN
4  ||| S:629 E:631 ||| CD
mkg ||| S:631 E:634 ||| CD
/ ||| S:634 E:635 ||| CD
ml ||| S:635 E:637 ||| CD
)  ||| S:637 E:639 ||| -RRB-
according  ||| S:639 E:649 ||| VBG
to  ||| S:649 E:652 ||| TO
the  ||| S:652 E:656 ||| DT
method  ||| S:656 E:663 ||| NN
of  ||| S:663 E:666 ||| IN
Schneider  ||| S:666 E:676 ||| NNP
Studied  ||| S:676 E:684 ||| NNP
parameters  ||| S:684 E:695 ||| NNS
were  ||| S:695 E:700 ||| VBD
defined  ||| S:700 E:708 ||| VBN
at  ||| S:708 E:711 ||| IN
the  ||| S:711 E:715 ||| DT
stages ||| S:715 E:721 ||| NNS
:  ||| S:721 E:723 ||| :
before  ||| S:723 E:730 ||| IN
the  ||| S:730 E:734 ||| DT
operation  ||| S:734 E:744 ||| NN
( ||| S:744 E:745 ||| -LRB-
I ||| S:745 E:746 ||| PRP
) ||| S:746 E:747 ||| -RRB-
,  ||| S:747 E:749 ||| ,
after  ||| S:749 E:755 ||| IN
the  ||| S:755 E:759 ||| DT
induction  ||| S:759 E:769 ||| NN
( ||| S:769 E:770 ||| -LRB-
II ||| S:770 E:772 ||| NNP
) ||| S:772 E:773 ||| -RRB-
,  ||| S:773 E:775 ||| ,
after  ||| S:775 E:781 ||| IN
the  ||| S:781 E:785 ||| DT
intubation  ||| S:785 E:796 ||| NN
( ||| S:796 E:797 ||| -LRB-
III ||| S:797 E:800 ||| NNP
) ||| S:800 E:801 ||| -RRB-
,  ||| S:801 E:803 ||| ,
during  ||| S:803 E:810 ||| IN
the  ||| S:810 E:814 ||| DT
separation  ||| S:814 E:825 ||| NN
of  ||| S:825 E:828 ||| IN
the  ||| S:828 E:832 ||| DT
carotid  ||| S:832 E:840 ||| JJ
artery  ||| S:840 E:847 ||| NN
( ||| S:847 E:848 ||| -LRB-
IV ||| S:848 E:850 ||| NNP
) ||| S:850 E:851 ||| -RRB-
,  ||| S:851 E:853 ||| ,
after  ||| S:853 E:859 ||| IN
the  ||| S:859 E:863 ||| DT
crossclamping  ||| S:863 E:877 ||| NN
of  ||| S:877 E:880 ||| IN
the  ||| S:880 E:884 ||| DT
carotid  ||| S:884 E:892 ||| JJ
artery  ||| S:892 E:899 ||| NN
( ||| S:899 E:900 ||| -LRB-
V ||| S:900 E:901 ||| NNP
) ||| S:901 E:902 ||| -RRB-
,  ||| S:902 E:904 ||| ,
before  ||| S:904 E:911 ||| IN
starting  ||| S:911 E:920 ||| VBG
the  ||| S:920 E:924 ||| DT
bloodstream  ||| S:924 E:936 ||| NN
( ||| S:936 E:937 ||| -LRB-
VI ||| S:937 E:939 ||| NNP
) ||| S:939 E:940 ||| -RRB-
,  ||| S:940 E:942 ||| ,
after  ||| S:942 E:948 ||| IN
starting  ||| S:948 E:957 ||| VBG
of  ||| S:957 E:960 ||| IN
the  ||| S:960 E:964 ||| DT
bloodstream  ||| S:964 E:976 ||| NN
( ||| S:976 E:977 ||| -LRB-
VII ||| S:977 E:980 ||| NNP
) ||| S:980 E:981 ||| -RRB-
,  ||| S:981 E:983 ||| ,
after  ||| S:983 E:989 ||| IN
the  ||| S:989 E:993 ||| DT
end  ||| S:993 E:997 ||| NN
of  ||| S:997 E:1000 ||| IN
the  ||| S:1000 E:1004 ||| DT
operation  ||| S:1004 E:1014 ||| NN
( ||| S:1014 E:1015 ||| -LRB-
VIII ||| S:1015 E:1019 ||| NNP
) ||| S:1019 E:1020 ||| -RRB-
.  ||| S:1020 E:1022 ||| .
At  ||| S:1022 E:1025 ||| IN
the  ||| S:1025 E:1029 ||| DT
first  ||| S:1029 E:1035 ||| JJ
stages  ||| S:1035 E:1042 ||| NNS
of  ||| S:1042 E:1045 ||| IN
the  ||| S:1045 E:1049 ||| DT
operation ||| S:1049 E:1058 ||| NN
,  ||| S:1058 E:1060 ||| ,
the  ||| S:1060 E:1064 ||| DT
using  ||| S:1064 E:1070 ||| VBG
of  ||| S:1070 E:1073 ||| IN
isoflurane ||| S:1073 E:1083 ||| NN
,  ||| S:1083 E:1085 ||| ,
sevoflurane  ||| S:1085 E:1097 ||| NN
and  ||| S:1097 E:1101 ||| CC
propofol  ||| S:1101 E:1110 ||| NNS
was  ||| S:1110 E:1114 ||| VBD
accompanied  ||| S:1114 E:1126 ||| VBN
with  ||| S:1126 E:1131 ||| IN
moderate  ||| S:1131 E:1140 ||| JJ
dose-dependent  ||| S:1140 E:1155 ||| JJ
lowering  ||| S:1155 E:1164 ||| NN
of  ||| S:1164 E:1167 ||| IN
indicators  ||| S:1167 E:1178 ||| NNS
ofcirculatory  ||| S:1178 E:1192 ||| JJ
dynamics ||| S:1192 E:1200 ||| NNS
.  ||| S:1200 E:1202 ||| .
The  ||| S:1202 E:1206 ||| DT
linear  ||| S:1206 E:1213 ||| JJ
blood  ||| S:1213 E:1219 ||| NN
flow  ||| S:1219 E:1224 ||| NN
velocity  ||| S:1224 E:1233 ||| NN
( ||| S:1233 E:1234 ||| -LRB-
LBFV ||| S:1234 E:1238 ||| NNP
)  ||| S:1238 E:1240 ||| -RRB-
in  ||| S:1240 E:1243 ||| IN
the  ||| S:1243 E:1247 ||| DT
middle  ||| S:1247 E:1254 ||| JJ
cerebral  ||| S:1254 E:1263 ||| JJ
artery  ||| S:1263 E:1270 ||| NN
on  ||| S:1270 E:1273 ||| IN
the  ||| S:1273 E:1277 ||| DT
affected  ||| S:1277 E:1286 ||| JJ
side  ||| S:1286 E:1291 ||| NN
in  ||| S:1291 E:1294 ||| IN
the  ||| S:1294 E:1298 ||| DT
groups  ||| S:1298 E:1305 ||| NNS
of  ||| S:1305 E:1308 ||| IN
isoflurane  ||| S:1308 E:1319 ||| NN
and  ||| S:1319 E:1323 ||| CC
propofol  ||| S:1323 E:1332 ||| NNS
did  ||| S:1332 E:1336 ||| VBD
not  ||| S:1336 E:1340 ||| RB
depend  ||| S:1340 E:1347 ||| VB
on  ||| S:1347 E:1350 ||| IN
the  ||| S:1350 E:1354 ||| DT
indicators  ||| S:1354 E:1365 ||| NNS
ofcirculatory  ||| S:1365 E:1379 ||| JJ
dynamics ||| S:1379 E:1387 ||| NNS
;  ||| S:1387 E:1389 ||| :
in  ||| S:1389 E:1392 ||| IN
the  ||| S:1392 E:1396 ||| DT
sevoflurane  ||| S:1396 E:1408 ||| JJ
group  ||| S:1408 E:1414 ||| NN
the  ||| S:1414 E:1418 ||| DT
correlation  ||| S:1418 E:1430 ||| NN
was  ||| S:1430 E:1434 ||| VBD
traced  ||| S:1434 E:1441 ||| VBN
During  ||| S:1441 E:1448 ||| IN
the  ||| S:1448 E:1452 ||| DT
breakoff  ||| S:1452 E:1461 ||| NN
of  ||| S:1461 E:1464 ||| IN
the  ||| S:1464 E:1468 ||| DT
blood  ||| S:1468 E:1474 ||| NN
circulation  ||| S:1474 E:1486 ||| NN
in  ||| S:1486 E:1489 ||| IN
the  ||| S:1489 E:1493 ||| DT
reconstructed  ||| S:1493 E:1507 ||| JJ
carotid  ||| S:1507 E:1515 ||| JJ
arteries  ||| S:1515 E:1524 ||| NNS
while  ||| S:1524 E:1530 ||| IN
using  ||| S:1530 E:1536 ||| VBG
the  ||| S:1536 E:1540 ||| DT
anesthesia  ||| S:1540 E:1551 ||| NN
of  ||| S:1551 E:1554 ||| IN
isoflurane ||| S:1554 E:1564 ||| NN
,  ||| S:1564 E:1566 ||| ,
sevoflurane  ||| S:1566 E:1578 ||| NN
and  ||| S:1578 E:1582 ||| CC
propofol  ||| S:1582 E:1591 ||| JJ
hemodynamics  ||| S:1591 E:1604 ||| NN
was  ||| S:1604 E:1608 ||| VBD
stable ||| S:1608 E:1614 ||| JJ
.  ||| S:1614 E:1616 ||| .
LBFV  ||| S:1616 E:1621 ||| NNP
and  ||| S:1621 E:1625 ||| CC
cerebral  ||| S:1625 E:1634 ||| JJ
oximetry  ||| S:1634 E:1643 ||| NNS
( ||| S:1643 E:1644 ||| -LRB-
CO ||| S:1644 E:1646 ||| NNP
)  ||| S:1646 E:1648 ||| -RRB-
in  ||| S:1648 E:1651 ||| IN
the  ||| S:1651 E:1655 ||| DT
groups  ||| S:1655 E:1662 ||| NNS
of  ||| S:1662 E:1665 ||| IN
isoflurane  ||| S:1665 E:1676 ||| NN
and  ||| S:1676 E:1680 ||| CC
propofol  ||| S:1680 E:1689 ||| NNS
did  ||| S:1689 E:1693 ||| VBD
not  ||| S:1693 E:1697 ||| RB
depend  ||| S:1697 E:1704 ||| VB
on  ||| S:1704 E:1707 ||| IN
the  ||| S:1707 E:1711 ||| DT
systemic  ||| S:1711 E:1720 ||| JJ
hemodynamics ||| S:1720 E:1732 ||| NN
;  ||| S:1732 E:1734 ||| :
in  ||| S:1734 E:1737 ||| IN
the  ||| S:1737 E:1741 ||| DT
sevoflurane  ||| S:1741 E:1753 ||| JJ
group--they  ||| S:1753 E:1765 ||| JJ
depended  ||| S:1765 E:1774 ||| NN
After  ||| S:1774 E:1780 ||| IN
the  ||| S:1780 E:1784 ||| DT
reinitiating  ||| S:1784 E:1797 ||| NN
of  ||| S:1797 E:1800 ||| IN
the  ||| S:1800 E:1804 ||| DT
bloodstream  ||| S:1804 E:1816 ||| NN
in  ||| S:1816 E:1819 ||| IN
the  ||| S:1819 E:1823 ||| DT
conditions  ||| S:1823 E:1834 ||| NNS
of  ||| S:1834 E:1837 ||| IN
the  ||| S:1837 E:1841 ||| DT
isoflurane  ||| S:1841 E:1852 ||| JJ
andpropofol  ||| S:1852 E:1864 ||| NNS
anesthesia  ||| S:1864 E:1875 ||| VBP
the  ||| S:1875 E:1879 ||| DT
reperfusion  ||| S:1879 E:1891 ||| NN
of  ||| S:1891 E:1894 ||| IN
the  ||| S:1894 E:1898 ||| DT
brain  ||| S:1898 E:1904 ||| NN
was  ||| S:1904 E:1908 ||| VBD
moderate ||| S:1908 E:1916 ||| JJ
;  ||| S:1916 E:1918 ||| :
in  ||| S:1918 E:1921 ||| IN
the  ||| S:1921 E:1925 ||| DT
conditions  ||| S:1925 E:1936 ||| NNS
of  ||| S:1936 E:1939 ||| IN
the  ||| S:1939 E:1943 ||| DT
sevoflurane  ||| S:1943 E:1955 ||| NN
anesthesia  ||| S:1955 E:1966 ||| VBD
the  ||| S:1966 E:1970 ||| DT
risk  ||| S:1970 E:1975 ||| NN
of  ||| S:1975 E:1978 ||| IN
reperfusion  ||| S:1978 E:1990 ||| JJ
damage  ||| S:1990 E:1997 ||| NN
of  ||| S:1997 E:2000 ||| IN
the  ||| S:2000 E:2004 ||| DT
brain  ||| S:2004 E:2010 ||| NN
during  ||| S:2010 E:2017 ||| IN
the  ||| S:2017 E:2021 ||| DT
uncontrolled  ||| S:2021 E:2034 ||| JJ
hypertension  ||| S:2034 E:2047 ||| NN
remained ||| S:2047 E:2055 ||| VBD
.  ||| S:2055 E:2057 ||| .
At  ||| S:2057 E:2060 ||| IN
the  ||| S:2060 E:2064 ||| DT
stage  ||| S:2064 E:2070 ||| NN
of  ||| S:2070 E:2073 ||| IN
finishing  ||| S:2073 E:2083 ||| VBG
the  ||| S:2083 E:2087 ||| DT
operation  ||| S:2087 E:2097 ||| NN
LBFV  ||| S:2097 E:2102 ||| NNP
and  ||| S:2102 E:2106 ||| CC
CO  ||| S:2106 E:2109 ||| NNP
did  ||| S:2109 E:2113 ||| VBD
not  ||| S:2113 E:2117 ||| RB
depend  ||| S:2117 E:2124 ||| VB
on  ||| S:2124 E:2127 ||| IN
the  ||| S:2127 E:2131 ||| DT
systemic  ||| S:2131 E:2140 ||| JJ
hemodynamics  ||| S:2140 E:2153 ||| NN
in  ||| S:2153 E:2156 ||| IN
the  ||| S:2156 E:2160 ||| DT
isoflurane  ||| S:2160 E:2171 ||| NN
and  ||| S:2171 E:2175 ||| CC
propofol  ||| S:2175 E:2184 ||| JJ
groups ||| S:2184 E:2190 ||| NNS
,  ||| S:2190 E:2192 ||| ,
in  ||| S:2192 E:2195 ||| IN
the  ||| S:2195 E:2199 ||| DT
sevoflurane  ||| S:2199 E:2211 ||| JJ
group  ||| S:2211 E:2217 ||| NN
the  ||| S:2217 E:2221 ||| DT
dependence  ||| S:2221 E:2232 ||| NN
was  ||| S:2232 E:2236 ||| VBD
indicated ||| S:2236 E:2245 ||| VBN
.  ||| S:2245 E:2247 ||| .
Consequently ||| S:2247 E:2259 ||| RB
,  ||| S:2259 E:2261 ||| ,
at  ||| S:2261 E:2264 ||| IN
all  ||| S:2264 E:2268 ||| PDT
the  ||| S:2268 E:2272 ||| DT
stages  ||| S:2272 E:2279 ||| NNS
of  ||| S:2279 E:2282 ||| IN
the  ||| S:2282 E:2286 ||| DT
operation  ||| S:2286 E:2296 ||| NN
we  ||| S:2296 E:2299 ||| PRP
indicated  ||| S:2299 E:2309 ||| VBD
the  ||| S:2309 E:2313 ||| DT
disorder  ||| S:2313 E:2322 ||| NN
of  ||| S:2322 E:2325 ||| IN
the  ||| S:2325 E:2329 ||| DT
mechanisms  ||| S:2329 E:2340 ||| NNS
of  ||| S:2340 E:2343 ||| IN
the  ||| S:2343 E:2347 ||| DT
brain  ||| S:2347 E:2353 ||| NN
blood  ||| S:2353 E:2359 ||| NN
supply  ||| S:2359 E:2366 ||| NN
autoregulation  ||| S:2366 E:2381 ||| NN
in  ||| S:2381 E:2384 ||| IN
the  ||| S:2384 E:2388 ||| DT
sevoflurane  ||| S:2388 E:2400 ||| JJ
group ||| S:2400 E:2405 ||| NN
.  ||| S:2405 E:2407 ||| .
